MDGL Stock MDGL is expected to report earnings to fall -9.68% to -623 cents per share on May 07

A.I.dvisor
at Tickeron.com
05/06/24
Loading...
MDGL - Madrigal Pharmaceuticals
Madrigal Pharmaceuticals Earnings Graph
Q1'24
Est.
$-6.23
Q4'23
Missed
by $0.44
Q3'23
Missed
by $0.44
Q2'23
Missed
by $0.10
Q1'23
Beat
by $0.73
The last earnings report on December 31 showed earnings per share of -568 cents, missing the estimate of -524 cents. P/B Ratio (12.063) is normal, around the industry mean (10.296). P/E Ratio (0.000) is within average values for comparable stocks, (116.129). MDGL's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.466). MDGL has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.015). P/S Ratio (0.000) is also within normal values, averaging (233.055). With 441.78K shares outstanding, the current market capitalization sits at 4.89B.
View a ticker or compare two or three
MDGLDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of small-molecule drugs addressing major unmet needs in cardiovascular and metabolic diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
200 Barr Harbor Drive
Phone
+1 267 824-2827
Employees
276
Web
http://www.madrigalpharma.com